KR20230147616A - 황색포도상구균 α-독소를 표적으로 하는 항원 결합단백질 및 이의 응용 - Google Patents

황색포도상구균 α-독소를 표적으로 하는 항원 결합단백질 및 이의 응용 Download PDF

Info

Publication number
KR20230147616A
KR20230147616A KR1020237027494A KR20237027494A KR20230147616A KR 20230147616 A KR20230147616 A KR 20230147616A KR 1020237027494 A KR1020237027494 A KR 1020237027494A KR 20237027494 A KR20237027494 A KR 20237027494A KR 20230147616 A KR20230147616 A KR 20230147616A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
binding protein
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237027494A
Other languages
English (en)
Korean (ko)
Inventor
마오마오 안
씨란 치우
시민 천
쉬유 구오
보화 리
Original Assignee
스타맵 바이오로직스 (쑤저우) 씨오., 엘티디
스타샤이닝 바이오로직스 (상하이) 씨오., 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타맵 바이오로직스 (쑤저우) 씨오., 엘티디, 스타샤이닝 바이오로직스 (상하이) 씨오., 엘티디 filed Critical 스타맵 바이오로직스 (쑤저우) 씨오., 엘티디
Publication of KR20230147616A publication Critical patent/KR20230147616A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020237027494A 2021-01-11 2022-01-11 황색포도상구균 α-독소를 표적으로 하는 항원 결합단백질 및 이의 응용 Pending KR20230147616A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110033695.3 2021-01-11
CN202110033695 2021-01-11
PCT/CN2022/071382 WO2022148480A1 (zh) 2021-01-11 2022-01-11 靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用

Publications (1)

Publication Number Publication Date
KR20230147616A true KR20230147616A (ko) 2023-10-23

Family

ID=82357142

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237027494A Pending KR20230147616A (ko) 2021-01-11 2022-01-11 황색포도상구균 α-독소를 표적으로 하는 항원 결합단백질 및 이의 응용

Country Status (7)

Country Link
US (1) US20240059764A1 (cg-RX-API-DMAC7.html)
EP (1) EP4286409A4 (cg-RX-API-DMAC7.html)
JP (1) JP7868059B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230147616A (cg-RX-API-DMAC7.html)
CN (1) CN117062908A (cg-RX-API-DMAC7.html)
BR (1) BR112023013790A2 (cg-RX-API-DMAC7.html)
WO (1) WO2022148480A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4410371A1 (en) * 2023-02-03 2024-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies against alpha-hemolysin from staphylococcus aureus
CN118480121B (zh) * 2024-05-13 2025-04-01 重庆原伦生物科技有限公司 一种特异性结合金黄色葡萄球菌蛋白a的抗体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
RS58190B2 (sr) * 2011-02-08 2021-08-31 Medimmune Llc Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene
US20140286960A1 (en) 2011-07-28 2014-09-25 Cangene Corporation Staphlococcus aureus alpha-hemolysin antibodies
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
US20190077851A1 (en) 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
WO2020041394A1 (en) * 2018-08-23 2020-02-27 Trustees Of Tufts College Binding proteins, compositions and methods thereof for neutralization of infection of pathogens having a type iii secretion system
CN109705213B (zh) * 2018-12-04 2023-04-18 上海长征医院 抗金黄色葡萄球菌毒素抗体及其用途
CN110577594B (zh) * 2019-08-19 2021-05-14 西北农林科技大学 一种金黄色葡萄球菌肠毒素a纳米抗体a21、应用及试剂盒
CN110526967A (zh) * 2019-08-19 2019-12-03 西北农林科技大学 一种金黄色葡萄球菌肠毒素a纳米抗体a13、应用及试剂盒
CN110526968B (zh) * 2019-08-19 2021-08-17 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b7、应用及试剂盒
CN110563839A (zh) * 2019-08-19 2019-12-13 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b1、应用及试剂盒
CN110526966B (zh) * 2019-08-19 2021-08-17 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b6、应用及试剂盒

Also Published As

Publication number Publication date
CN117062908A (zh) 2023-11-14
JP7868059B2 (ja) 2026-06-01
US20240059764A1 (en) 2024-02-22
EP4286409A4 (en) 2025-01-01
JP2024503425A (ja) 2024-01-25
BR112023013790A2 (pt) 2023-10-03
WO2022148480A1 (zh) 2022-07-14
EP4286409A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
JP7047017B2 (ja) 黄色ブドウ球菌(Staphylococcus aureus)α毒素に特異的に結合する抗体及び使用方法
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
TWI855236B (zh) 抗cd47/抗pd-l1抗體及其應用
TWI900705B (zh) Cd73的抗原結合蛋白及其應用
KR102058381B1 (ko) 인간 l1cam에 대한 인간화 항체 및 그의 제조 방법
KR101259239B1 (ko) PcrV에 대한 항체
JP2024502091A (ja) Pd-1結合分子およびその使用
EP4279507A1 (en) Cd73-binding protein and use thereof
JP2009524428A (ja) スタヒロコッカス・アウレウスorf0657nを標的とする抗原結合タンパク質
TW202611086A (zh) 特異性結合Claudin 18.2的抗體及其製法和應用
US20240059764A1 (en) ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF
CN114957460A (zh) 交叉中和金黄色葡萄球菌毒素的抗原结合蛋白及其用途
CN113264999B (zh) 中和肺炎链球菌溶血素蛋白的抗原结合蛋白及其用途
JP7773237B2 (ja) Cd47に対する単一ドメイン抗体及びその用途
EP4317182A1 (en) Antigen-binding protein targeting streptococcus pneumoniae hemolysin protein and use thereof
CN116284406B (zh) 一种pd-1结合蛋白及其应用
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP4292661A1 (en) Anti-vegf antibody and use thereof
CN119350502A (zh) 靶向fap的抗原结合蛋白及其应用
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
OA21956A (en) Antigen-binding protein targeting staphylococcus aureus α-toxin and application thereof.
OA21922A (en) Antigen-binding protein targeting streptococcus pneumoniae hemolysin protein and use thereof.
EP4219553A1 (en) Anti-tigit antibody and double antibody and their application
CN118715243A (zh) Cd39抗原结合蛋白及其应用
HK40089099A (en) Anti-tigit antibody and double antibody and their application

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230811

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250110

Comment text: Request for Examination of Application